PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
14768176-1	2003	Increased glucose metabolism through the hexosamine biosynthesis pathway has been shown to mediate many of adverse effects i.e. desensitisation of glucose transport in tissues, an inhibition of glycolysis and glycogen synthesis in skeletal muscles, an impairment of insulin secretion in pancreatic islet cells, arteriosclerosis and nephropathy by stimulation of growth factor TGF-alpha and TGF-beta 1 promoters expression.	Hexosamines	41-51	transforming growth factor beta 1	Homo sapiens	390-400	
14757763-0	2004	Upstream stimulatory factor (USF) proteins induce human TGF-beta1 gene activation via the glucose-response element-1013/-1002 in mesangial cells: up-regulation of USF activity by the hexosamine biosynthetic pathway.	Hexosamines	183-193	transforming growth factor beta 1	Homo sapiens	56-65	
14757763-1	2004	The hyperglycemia-enhanced flux through the hexosamine biosynthetic pathway (HBP) has been implicated in the up-regulated gene expression of transforming growth factor-beta1 (TGF-beta1) in mesangial cells, thus leading to mesangial matrix expansion and diabetic glomerulosclerosis.	Hexosamines	44-54	transforming growth factor beta 1	Homo sapiens	141-173	
14757763-1	2004	The hyperglycemia-enhanced flux through the hexosamine biosynthetic pathway (HBP) has been implicated in the up-regulated gene expression of transforming growth factor-beta1 (TGF-beta1) in mesangial cells, thus leading to mesangial matrix expansion and diabetic glomerulosclerosis.	Hexosamines	44-54	transforming growth factor beta 1	Homo sapiens	175-184	
11163803-1	2001	Increased flux through the hexosamine biosynthetic pathway with glutamine:fructose-6-phosphate-amidotransferase (GFAT) as rate-limiting enzyme has been linked to the enhanced bioactivity of the prosclerotic cytokine transforming growth factor beta1 (TGF-beta1) in fibrotic complications, particularly in diabetic kidney disease.	Hexosamines	27-37	transforming growth factor beta 1	Homo sapiens	216-248	
11163803-1	2001	Increased flux through the hexosamine biosynthetic pathway with glutamine:fructose-6-phosphate-amidotransferase (GFAT) as rate-limiting enzyme has been linked to the enhanced bioactivity of the prosclerotic cytokine transforming growth factor beta1 (TGF-beta1) in fibrotic complications, particularly in diabetic kidney disease.	Hexosamines	27-37	transforming growth factor beta 1	Homo sapiens	250-259	
10997685-3	2000	Several lines of evidence indicate that TGF-beta1 induction is mediated by the hexosamine pathway.	Hexosamines	79-89	transforming growth factor beta 1	Homo sapiens	40-49	
9421478-4	1998	Therefore, we suggested that the hexosamine biosynthetic pathway (the key enzyme of which is glutamine:fructose-6-phosphate amidotransferase [GFAT]) contributes to the high glucose-induced TGF-beta1 production.	Hexosamines	33-43	transforming growth factor beta 1	Homo sapiens	189-198	
9421478-6	1998	Overall, our study indicates that the flux of glucose metabolism through the GFAT catalyzed hexosamine biosynthetic pathway is involved in the glucose-induced mesangial production of TGF-beta leading to increased matrix production.	Hexosamines	92-102	transforming growth factor beta 1	Homo sapiens	183-191	
32722537-10	2020	Of these, RSV induces formation of nucleosome-free regions on TGFB1/JUNB//FN1/MMP9 genes and the rate limiting enzyme in the hexosamine biosynthetic pathway (HBP), Glutamine-Fructose-6-Phosphate Transaminase 2 (GFPT2).	Hexosamines	125-135	transforming growth factor beta 1	Homo sapiens	62-67	
28423621-4	2017	GFPT1 is the the key rate-limiting enzyme of the hexosamine signaling pathway and governs TGFbeta1 production.	Hexosamines	49-59	transforming growth factor beta 1	Homo sapiens	90-98